Advanced Oncotherapy announces positive results from study

Nicolas Serandour, CEO of Advanced Oncotherapy

Advanced Oncotherapy, the developer of a next-generation proton therapy system for cancer treatment, has announced positive results from its comparative study which further demonstrates the competitive advantages of the LIGHT system, the company’s proprietary proton accelerator.

The study, performed by Advanced Oncotherapy’s R&D team, ADAM, in Geneva, was aimed at comparing LIGHT against conventional cyclotrons which use energy degraders, the latter being the most commonly used accelerators in proton therapy technology today; its purpose was to compare the efficiency of both types of proton accelerators.

The analysis showed that LIGHT had a transmission of more than 95% for all the energies required to treat patients. In contrast, the transmission of a conventional cyclotron with energy degraders is less than 20% for an energy of 170MeV and less than 50% for an energy of 210MeV.

LIGHT has been designed to make cancer treatment using proton beam technology more affordable and accessible by lowering the costs associated with the extensive shielding requirements needed with traditional technologies.

‘Today’s results further enhance the tremendous opportunity for AVO to competitively differentiate its LIGHT system,’ said Nicolas Serandour, CEO of Advanced Oncotherapy. ‘LIGHT has been designed to tackle most of the costs associated with the set-up of a proton therapy centre whilst providing greater patient access. Due to the high efficiency of LIGHT at all energies, patient treatment times are not expected to depend on how deep their cancer is in their body. Having an efficient source of protons available for treatment is becoming more critical as patient daily treatment doses are following a rising trend, placing additional demand on the machine to avoid longer treatment times.’

Serandour went onto say that Advanced Oncotherapy is in the process of developing its first site in London’s Harley Street, which is expected to treat its first patients towards the end of 2020.